About the Commit Lozenge
Commit is approved by the FDA to help control tough cravings associated with quitting smoking(4). Commit has a unique dosage selector based on how soon a smoker smokes his first cigarette in the morning, so he can choose the strength that's right for him. The Commit lozenge helps people stop smoking by providing low, safe doses of NRT to ease withdrawal from cigarettes. Commit comes in different strengths -- 2 mg or 4 mg -- to be used depending on how soon a smoker has his first cigarette in the morning. The 2 mg dosage is for smokers who usually have their first cigarette more than thirty minutes after waking up. The 4 mg dosage is for smokers who usually have their first cigarette within thirty minutes of waking up.
About GlaxoSmithKline Consumer Healthcare
GSK Consumer Healthcare is one of the world's largest over-the-counter consumer healthcare products companies. GSK offers the widest range of proven NRT products available, products which can significantly improve a smoker's chance of quitting successfully and have helped millions of people quit smoking. In addition, GSK offers several resources and support services designed specifically to help smokers and non-smokers understand and address the two components to smoking cessation: nicotine addiction and habit change. Its more than 30 well-known brands include the leading smoking cessation products, Nicorette(R), NicoDerm(R) CQ and Commit(R) as well as many medicine cabinet staples, including Abreva(R), alli(R) Aquafresh(R), Sensodyne(R), Tums(R) and Breathe Right(R), trademarks owned and/or licensed to GlaxoSmithKline Group of Companies.
About GlaxoSmithKline
GlaxoSmithKline is one of the world's leading research-based
pharmaceutical and consumer healthcare companies. GlaxoSmithKline is
committed to improving the quality of human life by enabling people to do
more, feel better and live longer.
1. GSK Data on file, Study S254
'/>"/>
| SOURCE GlaxoSmithKline Consumer Healthcare Copyright©2008 PR Newswire. All rights reserved |